poisar

Stocks · News reference

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

BenzingaAug 27, 2026, 11:35 AMVandana Singh

VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 27, 2026, 11:35 AM
Checked
Aug 27, 2026, 11:35 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading